ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia

Main Article Content

Gabriele Magliano
Andrea Bacigalupo
(*) Corresponding Author:

Abstract

Acute myeloid leukemia (AML) in adults older than 60 years old has a poor prognosis. Elderly patients often present with comorbidities and an adverse biology of the disease, with higher genetic risk and chemoresistance.  Allogeneic hematopoietic stem cell transplantation (HSCT) can be an effective treatment, and can improve overall survival (OS).Intensive chemotherapy (IC) before HSCT and  myeloablative conditioning regimens can produce significant toxicity and transplant-related mortality (TRM). Reduced-intensity conditioning (RIC) or non-myeloablative (NMA) regimens appear to preserve the graft-versus-leukemia effect, and may improve survival. The increasing knowledge in  AML of the elderly  is  currently being associated with  a multidimensional approach to identify those patients eligible for targeted therapy, such as Flt3 inhibitors, and/or allogeneic HSCT.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

[1] Hilberink J, Hazenberg C, van den Berg E, Mulder A, Schuringa JJ, van der Helm L, de Groot M, Choi G, de Bock GH, Vellenga E, Ammatuna E, Huls G.Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients. Leuk Res.2019 May;80:33-39.[DOI][PubMed][GoogleScholar]

[2] Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M.Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009 Apr 30;113(18):4179-87[DOI][PubMed][GoogleScholar]

[3] Rosko A, ArtzA.Aging: Treating the Older Patient.Biol Blood Marrow Transplant .2017 February ; 23(2): 193–200[DOI][PubMed][Google Scholar][PMC Free Article]

[4] SekeresMA.Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives. Haematologica. 2008; 93(12):1769-72[DOI][PubMed][Google Scholar]

[5] Goyal G, Gundabolu K, Vallabhajosyula S, Silberstein PT, Bhatt VR.Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.Ther Adv Hematol. 2016 Jun;7(3):131-41.[DOI][PubMed][Google Scholar][PMC Free Article]

[6] Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Biol Blood Marrow Transplant. 2016 Apr;22(4):651-657[DOI][PubMed][Google Scholar][PMC Free Article]

[7] Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M; Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012 Apr 26;119(17):3890-9[DOI][PubMed][Google Scholar][PMC Free Article]
[8] Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (19732002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submissionwww.seer.cancer.gov

[9] Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A..Increasing use of allogeneic hematopoietic cell transplantation in patientsaged 70 years and older in the United States. Blood. 2017 Aug 31;130(9):1156-1164[DOI][PubMed][Google Scholar][PMC Free Article]

[10] Brunner AM , Kim HT, Coughlin E, Alyea EP 3rd, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB.Outcomes in patientsage 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood MarrowTransplant. 2013 Sep;19(9):1374-80 [DOI][PubMed][Google Scholar]

[11] Artz AS. From biology to clinical practice: aging and hematopoietic cell transplantation. Biol Blood MarrowTransplant. 2012;18:S40-S45.[DOI][PubMed][Google Scholar]

[12] Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371:2488–2498. [DOI][PubMed][Google Scholar][PMC Free Article]

[13] Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006 May 1;107(9):3481-5[DOI][PubMed][Google Scholar][PMC Free Article]
[14] McMurray MA, Gottschling DE. An age-induced switch to a hyper-recombinational state. Science. 2003;301:1908-1911.[DOI][PubMed][Google Scholar]

[15] Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL.. The aging of hematopoietic stem cells. NatMed. 1996;2: 1011-1016.[DOI][PubMed][Google Scholar]

[16] Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 1998;16: 743-747.[DOI][PubMed][Google Scholar]

[17] Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000;14: 636-641. [DOI][PubMed][Google Scholar]

[18] Oran B, Weisdorf DJ. Survival for olderpatients with acute myeloid leukemia: a population-based study. Haematologica. 2012 Dec;97(12):1916-24[DOI][PubMed][Google Scholar][PMC Free Article]

[19] Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE; Medical Research Council Adult Leukemia Working Party.Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98: 1302-1311.[DOI][PubMed][Google Scholar]

[20] Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH; Medical Research Council Adult Leukemia Working Party.The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML); analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98: 1312-1320.[DOI][PubMed][Google Scholar]

[21] Moorman AV, Roman E, Willett EV, Dovey GJ, Cartwright RA, Morgan GJ..Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet Cytogenet. 2001;126: 155-161.[DOI][PubMed][Google Scholar]
[22] Fairman J, Wang RY, Liang H, Zhao L, Saltman D, Liang JC, Nagarajan L.Translocations and deletions of 5q13.1 in myelodysplasia and acute myelogenous leukemia: evidence for a novel critical locus. Blood. 1996;88: 2259-2266.[PubMed][Google Scholar]

[23] Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J ClinOncol. 2001;19: 1405-1413[DOI][PubMed][Google Scholar]

[24] Cancer and Leukemia Group B 8461,Farag SS, Archer KJ,Mrózek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD.Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood.2006 Jul 1;108(1):63-73[DOI][PubMed][Google Scholar][PMC Free Article]

[25] Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH .The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol.2006 Oct;135(2):165-73 [DOI][PubMed][Google Scholar]

[26] Leith CP, Kopecky KJ, Chen IM,Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CR. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99.[DOI][PubMed][Google Scholar]

[27] Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119:2720-2727. [DOI][PubMed][Google Scholar][PMC Free Article]

[28] Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia.Blood. 2016;127(1):53-61. [DOI][PubMed][Google Scholar][PMC Free Article]
[29] Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012.Leukemia.2016 Jan;30(1):24-31 [DOI][PubMed][Google Scholar] [30] Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program .2012;2012:1-6.[DOI][PubMed][Google Scholar]
[31] Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576 [DOI] [PubMed] [Google Scholar]

[32] Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-2677 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[33] Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE on behalf of the Medical Research Council Adult Leukaemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311. [DOI] [PubMed] [Google Scholar]

[34] Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW, Norwood TH, Chen IM, Balcerzak SP, Johnson DB, Appelbaum FR. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100: 3869-3876. [DOI] [PubMed] [Google Scholar]

[35] Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila L, Vignetti M, de Witte T. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organization for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leukemia. 2005;19:1768-1773. [DOI] [PubMed] [Google Scholar]

[36] Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMN Cancer. 2009 Jul 26;9:252 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[37] Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, Sandmaier BM, Witherspoon RP, Nash RA, Sanders JE, Bedalov A, Hansen JA, Clurman BE, Storb R, Appelbaum FR, Deeg HJ. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007 Aug 15;110(4):1379-87 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[38] Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, Van Lint MT, Gobbi M , Miglino M , Clavio M , Risso M, Frassoni F, Bacigalupo A. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant 40: 349–354. [DOI] [PubMed] [Google Scholar]

[39] Muffly L.Transplant for Acute Myeloid Leukemia in Patients Seventy Years and Older: Optimism and Opportunity. Biol Blood Marrow Transplant. 2019 Oct;25(10):e301-e302 [DOI] [PubMed] [Google Scholar]

[40] Ustun C, Lazarus HM, Weisdorf D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 2013;48:1497-1505 [DOI] [PubMed] [Google Scholar]

[41] Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395-400. [DOI] [PubMed] [Google Scholar]

[42] Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A.Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant.2019 Oct;25(10):1975-1983 [DOI] [PubMed] [Google Scholar]

[43] Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, Abonour R, Cornetta K, Cripe LD. Long term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant 45: 1300–1308. [DOI] [PubMed] [Google Scholar]


[44] Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK. Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older. J Clin Oncol. 2005; 23:3439-3446 [DOI] [PubMed] [Google Scholar]

[45] Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15: 1628–1633. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[46] Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B. Reduced intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant.2009; 15: 367–369. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[47] Haen SP, Pham M , Faul C ,Dörfel D , Vogel W , Kanz L ,Bethge WA. Allogeneic hematopoietic cell transplantation in patients ?70 years: which patients may benefit?. Blood Cancer Journal .2016; 6: e 443 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[48] Storb, R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol. 2007; 20: 85–90. [DOI] [PubMed] [Google Scholar]

[49] Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011; 306: 1874–1883 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[50] Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, Gribben JG. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. Br J Haematol . 2013;162: 525–529 [DOI] [PubMed] [Google Scholar]

[51] McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J ClinOncol. 2010;28: 1878–1887. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[52] Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015; 2: e427–36. [DOI] [PubMed] [Google Scholar]

[53] Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trial in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J ClinOncol. 2015; 33: 4167–4175. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[54] Herr AL, Labopin M, Blaise D, Milpied N, Potter M, Michallet M, Heit W, Ferrara F, Esteve J, Arcese W, Ehninger G, Rowe JM, Kobbe G, Rosselet A, Bunjes D, Rio B, Brune M, Nagler A, Gorin NC, Frassoni F, Rocha V; Acute Leukemia Working Party or the European Group for Blood and Marrow Transplantation. HLA identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia. 2007; 21: 129–135. [DOI] [PubMed] [Google Scholar]

[55] Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, De Angelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ. Comparative outcome of non myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810 4. [DOI] [PubMed] [Google Scholar]

[56] Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, Finke J, Schwerdtfeger R, Eder M, Bunjes D, Gorin NC, Mohty M, Rocha V.Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J ClinOncol. 2009; 27: 4570–4577 [DOI] [PubMed] [Google Scholar]

[57] Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?.Blood.2013 Mar 28;121(13):2567-2573 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[58] Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huyn A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? Bone Marrow Transplant.2015; 50: 1411–1415. [DOI] [PubMed] [Google Scholar]

[59] Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, Vazquez L, Caballero D, Del Cañizo C.Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodysplastic syndrome. Leuk Res. 2015; 39: 828–834. [DOI] [PubMed] [Google Scholar]

[60] Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M.Haploidentical transplant with post transplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20;126(8):1033-40. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[61] Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index Biol Blood Marrow Transpl. 2016; 22: 125-133 [DOI] [PubMed] [Google Scholar]

[62] Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose posttransplantation cyclophosphamide in older adults. J Clin Oncol. 2015; 33: 3152–3161. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[63] Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant. 2012; 47: 494–498. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[64] Sandhu KS, Brunstein C, DeFor T, Bejanyan N, Arora M, Warlick E, Weisdorf D, Ustun C.Umbilical cord blood transplantation outcomes in acute myelogenous leukemia/myelodysplastic syndrome patients aged ?70 years. Biol Blood Marrow Transplant; 2016:22: 390–393. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[65] Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A. Unmanipulated haploidentical bone marrow transplantation and post transplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22 [DOI] [PubMed] [Google Scholar]

[66] Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, Bejanyan N, Warlick E, Brunstein C, Weisdorf DJ, Linden MA.Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia. Biol Blood Marrow Transplant. 2015 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[67] Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ. Long-term survival in refractory acute myeloid leukemia after sequential allogeneic stem cell transplantation treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006 108: 1092-1099 [DOI] [PubMed] [Google Scholar]

[68] Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117(25):6768-6776. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[69] Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, Pape L, Extermann M, Van Besien K, Artz AS. Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients Biol Blood Marrow Transplant 19 (2013); 429e434. [DOI] [PubMed] [Google Scholar]

[70] Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824-1831. [DOI] [PubMed] [Google Scholar]

[71] Artz AS. Comorbidity and beyond: pre-transplant clinical assessment. Bone Marrow Transplant. 2005;36:473-474. [DOI] [PubMed] [Google Scholar]

[72] Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B.Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106:2912–2919. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[73] Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC.Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015; 21:1479–1487. [DOI] [PubMed] [Google Scholar] [PMC Free Article]
[74] Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer. 2016; 122:91–98. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[75] Wood WA, Deal AM, Reeve BB, Abernethy AP, Basch E, Mitchell SA, Shatten C, Hie Kim Y, Whitley J, Serody JS, Shea T, Battaglini C. Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study. Bone Marrow Transplant. 2013; 48:1342–1349. [DOI] [PubMed] [Google Scholar]

[76] Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR; from the Center for International Blood and Marrow Transplantation Research. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016 Nov;101(11):1426-1433. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[77] Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014; 99:1373–1379. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[78] Armand Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT. Blood. 2012;120:905-913. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[79] Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, Terré C, Rigaudeau S, Bordessoule D, Vey N, Gardin C, Dombret H; Acute Leukemia French Association (ALFA). Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008;93:1806-1813. [DOI] [PubMed] [Google Scholar]

[80] Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood.2010;116(22):4422-9. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[81] Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE.Age and modified European LeukemiaNet classification to predict transplant outcomes: an integrated approach for acute myelogenous leukemia patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant.2015; 21: 1405–1412. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[82] Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020 Jul 16:JCO1903345 [DOI] [PubMed] [Google Scholar]

[83] Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M.Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.Leuk Res 2010; 34: 752-6 [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[84] Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V.Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30:735–741, 2012 [DOI] [PubMed] [Google Scholar]

[85] Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.NEngl J Med 2017; 377: 454-64. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[86] Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R):a multicentre, randomised, controlled,open-label, phase 3 trial. Lancet Oncol2019; 20: 984-97. [DOI] [PubMed] [Google Scholar]

[87] Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as atherapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260-3. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[88] Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 2017;129: 257-60. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[89] Perl Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.Gilteritinib or Chemotherapy for Relapsedor Refractory FLT3-Mutated AML.N Engl J Med2019;381:1728-40 [DOI] [PubMed] [Google Scholar]

[90] Wayne AS, Giralt S, Kröger N, Bishop MR. Proceedings from the National Cancer Institute’s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: introduction. Biol Blood Marrow Transplant.2013; 19: 1534–1536. [DOI] [PubMed] [Google Scholar] [PMC Free Article]

[91] Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ. Proceedings from the National Cancer Institute’s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant.2013; 19: 1537–1545. [DOI] [PubMed] [Google Scholar]

[92] Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, Liu GX, Sun WJ, Wei L, Sun XD, Huang YJ, Qiao JX, Dong Z, Ai HS. Infusion of HLA-mismatched Therapeutic Advances in Hematology 7(3) peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011; 117: 936–941. [DOI] [PubMed] [Google Scholar]






.

Most read articles by the same author(s)